Opinion
Video
Ronald D. Alvarez, MD, MBA, provides closing commentary on the current ovarian cancer treatment landscape and the promising outlook over the next 20 years.
FDA Approves Fitusiran for Reducing Bleeds in Patients With Hemophilia A/B
Five Years Later: Ongoing COVID-19 Challenges, Next Steps
Speech Recognition Tools May Boost Clinician Documentation Efficiency
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
FDA Approves Cabozantinib for Advanced Pancreatic Neuroendocrine Tumors
PAH Therapies Improve Outcomes in PH-ILD